Evidence map›Paper›PMID 37107199›Full record

ArticleAntioxidants (Basel, Switzerland)2023

Novel Reversible Inhibitors of Xanthine Oxidase Targeting the Active Site of the Enzyme.

Rosario Rullo, Carmen Cerchia, Rosarita Nasso, Virgilio Romanelli, Emmanuele De Vendittis, Mariorosario Masullo, Antonio Lavecchia

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. AMB Express · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Identification ofMetabolites · 2024
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Rosario RulloInstitute for the Animal Production Systems in the Mediterranean Environment, CNR, 80055 Portici, Italy.
Carmen CerchiaDepartment of Pharmacy, "Drug Discovery" Laboratory, University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0002-6631-5000
Rosarita NassoDepartment of Human Movement Sciences and Wellness, University of Naples "Parthenope", 80133 Naples, Italy.
Virgilio RomanelliDepartment of Pharmacy, "Drug Discovery" Laboratory, University of Naples Federico II, 80131 Naples, Italy.ORCID 0009-0005-2931-4147
Emmanuele De VendittisDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
Mariorosario MasulloDepartment of Human Movement Sciences and Wellness, University of Naples "Parthenope", 80133 Naples, Italy.ORCID 0000-0003-4485-7383
Antonio LavecchiaDepartment of Pharmacy, "Drug Discovery" Laboratory, University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0002-2181-8026
University of Naples Federico II · ITParthenope University of Naples · ITIstituto per il Sistema Produzione Animale in Ambiente Mediterraneo · IT

Funding

MUR (Italy), promotion and policy development fund of the National Research Programme (PNR)-DM737 of 25-06-2021 CUP I55F21003620001
6 · The paper itself

Abstract

Xanthine oxidase (XO) is a flavoprotein catalysing the oxidation of hypoxanthine to xanthine and then to uric acid, while simultaneously producing reactive oxygen species. Altered functions of XO may lead to severe pathological diseases, including gout-causing hyperuricemia and oxidative damage of tissues. These findings prompted research studies aimed at targeting the activity of this crucial enzyme. During the course of a virtual screening study aimed at the discovery of novel inhibitors targeting another oxidoreductase, superoxide dismutase, we identified four compounds with non-purine-like structures, namely

Indexed as

drug discoverykinetic studiesredox enzymesxanthine oxidasexanthine oxidase inhibitors

Identifiers

PMID37107199
PMCPMC10135315
OpenAlexW4361206171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.